Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study

Richard J Huntsman, Richard Tang-Wai, Jane Alcorn, Stephanie Vuong, Bryan Acton, Scott Corley, Robert Laprairie, Andrew W Lyon, Simona Meier, Darrell D Mousseau, Doris Newmeyer, Erin Prosser-Loose, Blair Seifert, Jose Tellez-Zenteno, Linda Huh, Edward Leung, Philippe Major, Richard J Huntsman, Richard Tang-Wai, Jane Alcorn, Stephanie Vuong, Bryan Acton, Scott Corley, Robert Laprairie, Andrew W Lyon, Simona Meier, Darrell D Mousseau, Doris Newmeyer, Erin Prosser-Loose, Blair Seifert, Jose Tellez-Zenteno, Linda Huh, Edward Leung, Philippe Major

Abstract

Purpose: There is uncertainty regarding the appropriate dose of Cannabidiol (CBD) for childhood epilepsy. We present the preliminary data of seven participants from the Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) study. Methods: The study is an open-label, prospective, dose-escalation trial. Participants received escalating doses of a Cannabis Herbal Extract (CHE) preparation of 1:20 Δ9-tetrahydrocannabinol (THC): CBD up to 10-12 mg CBD/kg/day. Seizure frequency was monitored in daily logs, participants underwent regular electroencephalograms, and parents filled out modified Quality of Life in Childhood Epilepsy (QOLCE) and Side Effect rating scale questionnaires. Steady-state trough levels (Css, Min) of selected cannabinoids were quantified. Results: All seven participants tolerated the CHE up to 10-12 mg CBD/kg/day and had improvements in seizure frequency and QOLCE scores. CSS, Min plasma levels for CBD, THC, and cannabichromene (CBC) showed dose-independent pharmacokinetics in all but one participant. CSS, Min CBD levels associated with a >50% reduction in seizures and seizure freedom were lower than those reported previously with purified CBD. In most patients, CSS, Min levels of THC remained lower than what would be expected to cause intoxication. Conclusion: The preliminary data suggest an initial CBD target dose of 5-6 mg/kg/day when a 1:20 THC:CBD CHE is used. Possible non-linear pharmacokinetics of CBD and CBC needs investigation. The reduction in seizure frequency seen suggests improved seizure control when a whole plant CHE is used. Plasma THC levels suggest a low risk of THC intoxication when a 1:20 THC:CBD CHE is used in doses up to 12 mg/kg CBD/kg/day.

Keywords: cannabidiol; cannabinoid plasma levels; cannabis; epileptic encephalopathy; Δ9-tetrahydrocannabinol.

Figures

Figure 1
Figure 1
(A) Percentage reduction in daily average seizure frequency as compared to baseline. The value shown at each visit represents the decrease in seizure frequency from baseline during the preceding month. (B) Average percentage reduction in daily average seizure frequency from baseline for all seven participants at each study visit. (C) Average percentage reduction in daily seizure frequency from baseline for all seven participants broken down into seizure type. Data are shown as mean ± s.e.m.
Figure 2
Figure 2
Pooled QOLCE-55 scores and subscores for all seven participants. The values shown at each visit represent the QOLCE-55 total and subscores for the preceding month. Data are mean from seven participants.
Figure 3
Figure 3
Participant minimum steady state (CSS,Min) plasma concentrations and average plasma CSS,Min levels for each cannabinoid of cannabidiol (CBD) (A,B), cannabichromene (CBC) (C,D), and Δ9-tetrahydrocannabinol (THC) (E,F) analyzed with LC-MS/MS. Values shown represent steady state levels after 1 month on the corresponding dosage of CBD measured just prior to a dose administration. Data are mean ± s.e.m.

References

    1. Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, et al. . CBD enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure. (2016) 35:41–4. 10.1016/j.seizure.2016.01.004
    1. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. . Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. (2016) 15:270–8. 10.1016/S1474-4422(15)00379-8
    1. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. . Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. (2017) 376: 2011–20. 10.1056/NEJMoa1611618
    1. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome(GWPCARE4); a randomized, double blind, placebo controlled phase 3 trial. Lancet. (2018) 391:1085–96. 10.1016/S0140-6736(18)30136-3
    1. McCoy B, Wang L, Zak M, Al-Mehmadi S, Kabir N, Alhadid K, et al. . A prospective open label trial of a CBD/THC cannabis oil in Dravet syndrome. Ann Clin and Transl Neur. (2018) 5:1077–88 10.1002/acn3.621
    1. van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. In: Seyberth H, Rane A, Schwab M. editors. Pediatric Clinical Pharmacology. Handbook of Experimental Pharmacology, Vol. 205. Berlin; Heidelberg: Springer; (2011). p. 51–75. 10.1007/978-3-642-20195-0_2
    1. Reithmeier D, Tang-Wai R, Seifert B, Lyon AW, Alcorn J, Acton B, et al. . The protocol for the Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) study: a phase 1 dosage escalation study. BMC Pediatrics. (2018) 18:221–30. 10.1186/s12887-018-1191-y
    1. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. . Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. (2010) 51:1069–77. 10.1111/j.1528-1167.2009.02397.x
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. (2009) 42:377–81. 10.1016/j.jbi.2008.08.010
    1. Lüders HO, Noachtar S. Atlas and Classification of Electroencephalography, Illustrated. Philadelphia, PA: Wb Saunders; (2000).
    1. Connolly AM, Sabaz M, Lawson JA, Bye AME, Cairns DR. Quality of life in childhood epilepsy; validating the QOLCE. J Paediatr Child Health. (2005) 41:156–8. 10.1111/j.1440-1754.2005.570_2.x
    1. Vuong S, Michel D, Alcorn J, Huntsman R, Tang-Wai R, Lyon AW. BD. Vacutainer® Barricor® Blood Collection Tube is the Tube of Choice for LC-MS/MS Analysis of Bioactive Cannabinoids in Plasma. (2018). Available online at: (accessed March 13, 2019).
    1. Barco S, Fucile C, Manfredini L, De Grandis E, Gherzi M, Martelli A, et al. A UHPLC-MS method for the quantification of Δ9-tetrahydrocannabinol and cannabidiol in decoctions and in plasma samples for therapeutic monitoring of medical cannabis. Bioanalysis. (2018) 10:2003–14. 10.4155/bio-2018-0184
    1. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. (2015) 56:1246–51. 10.1111/epi.13060
    1. Bornheim LM, Everhart ET, Li J, Correia MA. Characterization of cannabidiol-mediated cytochrome p450 inactivation. Biochem Pharmcol. (1993) 45:1323–3. 10.1016/0006-2952(93)90286-6
    1. Sonmez FM, Demir E, Orem A, Yildirmis S, Orhan F, Aslan A, et al. . Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J Child Neurol. (2006) 21:70–4. 10.1177/08830738060210011301
    1. Health Canada. Information for Health Care Professionals: Cannabis (Marihuana, Marijuana) and the Cannabinoids. (2013). Available online at: (accessed March 13, 2019).
    1. May TW, Boor R, Mayer T, Jürgens U, Rambeck B, Holert N, et al. . Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age and comedication. Ther Drug Monit. (2012) 34:390–7. 10.1097/FTD.0b013e31825dc4a6
    1. Ohlsson A, Lindgren J-E, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. (1980) 28:409–16. 10.1038/clpt.1980.181
    1. Zuardi AW, Hallak JE, Crippa JA. Interaction between cannabidiol (CBD) and (9)-tetrahydrocannabinol (THC) influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology. (2012) 219:247–9. 10.1007/s00213-011-2495-x
    1. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. (2007) 4:1770–804. 10.1002/cbdv.200790152
    1. Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Presented at: Marijuana'90. In: International Conference on Cannabis and Cannabinoids, Crete (1990).
    1. Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, et al. . Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. (2018) 89:741–53. 10.1136/jnnp-2017-317168
    1. Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, et al. . Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs. (2018) 78:1791–804. 10.1007/s40265-018-0992-5
    1. Russo EB. Taming THC: potential cannabis synergy and phytocannbinoid-terpenoid entourage effects. Brit J Pharmacol. (2011) 163:1344–64. 10.1111/j.1476-5381.2011.01238.x
    1. Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S, et al. . Medicinal Cannabis; is delta9-tetrahydrocannabinol necessary for its effects? J Pharm Pharmacol. (2003) 55:1687–94. 10.1211/0022357022304
    1. Ryan D, Drysdale AJ, Pertwee RG, Platt B. Differential effects of cannabis extracts and pure cannabinoids on hippocampal neurons and glia. Neurosci Lett. (2006) 408:236–41. 10.1016/j.neulet.2006.09.008
    1. Pamplona FA, da Silva LR, Coan AC. Potential clinical benefits of CBD-rich Cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. (2018) 9:759 10.3389/fneur.2018.00759
    1. Campbell CT, Shaw Phillips M, Manasco K. Cannabinoids in pediatrics. J Pediatr Pharmacol Ther. (2017) 22:176–85. 10.5863/1551-6776-22.3.176
    1. Szutorisz H, Hurd YL. Epigenetic effects of Cannabis exposure. Biol Psychiatry. (2016) 79:586–94. 10.1016/j.biopsych.2015.09.014
    1. Van Cott AC, Brenner RP. Drug effects and toxic encephalopathies. In: Ebersole JS, Pedley TA. editors: Current Practice in Clinical Electroencephalography, 3rd edition. Philadelphia, PA: Lippincott Williams and Wilkins. (2003).

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel